Date: 2015-02-05
Type of information: Grant
Company: Thrombogenics (Belgium)
Investors: Flemish Agency for Innovation by Science and Technology (IWT) (Belgium)
Amount: €1.1 million
Funding type: grant
Planned used: The grant will be used by Thrombogenics to fund the on-going research to further elucidate the pharmacological effects ocriplasmin (Jetrea®) is exerting in the back of the eye following intravitreal (IVT) injection. In the US, truncated form of human plasmin is indicated for the treatment of symptomatic VMA. In Europe, Jetrea® is indicated for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns. Jetrea® is a selective proteolytic enzyme that cleaves fibronectin, laminin and collagen, three major components of the vitreoretinal interface that play an important role in vitreomacular adhesion.
Others: * On February 5, 2015, ThromboGenics, an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announced that it has been awarded a €1.1 million research grant from the Flemish agency for Innovation by Science and Technology (IWT). The grant will be used by Thrombogenics to fund the on-going research to further elucidate the pharmacological effects ocriplasmin is exerting in the back of the eye following intravitreal (IVT) injection.
Therapeutic area: Ophtalmological diseases
